CURRENT STUDIES

Learn more about our upcoming and ongoing research opportunities.

The Selection Study

Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction...

>> Learn More >> Apply to Volunteer

U-Excel Study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects...

>> Learn More >> Apply to Volunteer

U-Exceed Study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects...

>> Learn More >> Apply to Volunteer

Lucent 1 & Lucent 2 Studies

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizmab in Conventional-Failed and Biologic-Failed Patents...

>> Learn More >> Apply to Volunteer

Nexvax2-2006

A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease To Assess the Effect...

>> Learn More >> Apply to Volunteer

The Selection Study

Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction...

>> Learn More

U-Excel Study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects...

>> Learn More

U-Exceed Study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects...

>> Learn More

Lucent 1 & Lucent 2 Studies

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizmab in Conventional-Failed and Biologic-Failed Patents...

>> Learn More

Nexvax2-2006

A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease To Assess the Effect...

>> Learn More